Analysis of clinical, iconographical and pathological characteristics, prognosis and treatment methods for 35 cases of Langerhans cell histiocytosis.
10.7534/j.issn.1009-2137.2014.04.042
- Author:
Hua YANG
1
;
Xiao-Ping HAN
1
;
Bao-Jing LI
2
;
Lu SUN
3
;
Hai-Yan ZHU
1
;
Fei LI
1
;
Quan-Shun WANG
1
;
Wen-Rong HUANG
1
;
Jian BO
1
;
Yu ZHAO
1
;
Hong-Hua LI
1
;
Shu-Hong WANG
1
;
Li YU
1
;
Yu JING
4
Author Information
1. Department of Haematology, Chinese PLA General Hospital, Beijing 100853, China.
2. Department of Oncology, Baoding Hengxing Hospital of Traditional Chinese Medicine Integrated with Westen Medicine, Baoding 071051, Hebei Province, China.
3. Department of Pathology, Chinese PLA General Hospital, Beijing 100853, China.
4. Department of Haematology, Chinese PLA General Hospital, Beijing 100853, China. E-mail: jingyu301@126.com.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Child;
Child, Preschool;
Female;
Histiocytosis, Langerhans-Cell;
diagnosis;
drug therapy;
pathology;
Humans;
Infant;
Male;
Middle Aged;
Prognosis;
Retrospective Studies;
Young Adult
- From:
Journal of Experimental Hematology
2014;22(4):1109-1114
- CountryChina
- Language:Chinese
-
Abstract:
Purpose of this study was to analyse the characteristics of clinical, iconographical, pathological and treatment methods of Langerhans cell histiocytosis (LCH), so as to improve the diagnosis and treatment level of this disease. The clinical data of 35 LCH patients were studied retrospectively. These patients were divided into 2 groups according to age <14 years old and ≥ 14 years old. The clinical symptoms were analysed and the signs, imageology and pathology manifestation and treatment results were evaluated. The results showed that LCH clinical manifestations were diverse and complex. Surgical treatment for patients with single system involvement of LCH was better than that of multi-system involvement of LCH (MS-LCH). For the latter, combined chemotherapy effects was better. After 3-year follow-up, 1-year OS was 94% ± 4%, 2-years OS was 91% ± 5%, 3-year OS was 86% ± 7%. 3 years OS of group <14 years old and ≥ 14 years old was 94% ± 6% and 81% ± 10% respectively. The OS of former was better than that of the later, but because a small number of cases, this difference was not statistically significant. It is concluded that LCH is easy to be misdiagnosed, the pathological biopsy is the gold standard of LCH diagnosis. The PET-CT can be of great help in identifying stages and finding lesion areas of the disease. Pulmonary Langerhans cell histiocytosis (PLCH) is more common in adult. Combined chemotherapy can improve the prognosis of the patients. The treatment methods should be choosed according to the stage and classification of disease.
